Table 1.
Cancer Drug List (CDL) for lymphoma treatment in Singapore (as of 1 Apr 2023)
| Drug name | Clinical indication |
|---|---|
| Acalabrutinib | Mantle cell lymphoma; received at least one prior therapy |
| Bexarotene | Cutaneous T-cell lymphoma; received at least one prior systemic therapy |
| Brentuximab vedotin | CD30 + peripheral T-cell lymphoma; previously untreated |
| Brentuximab vedotin | CD30 + cutaneous T-cell lymphoma; received at least 1 prior systemic therapy |
| Brentuximab vedotin | Relapsed or refractory CD30 + Hodgkin lymphoma; following ASCT or at least two prior therapies when ASCT or multi-agent chemotherapy is not an option |
| Brentuximab vedotin | Relapsed or refractory systemic anaplastic large cell lymphoma |
| Brentuximab vedotin | Consolidation treatment of CD30 + Hodgkin lymphoma who are at increased risk of relapse or progression following ASCT |
| Brentuximab vedotin | Previously untreated CD30 + advanced classic Hodgkin lymphoma |
| Copanlisib | Relapsed follicular lymphoma who have received at least two prior systemic therapies |
| Crisantaspase | Hypersensitivity to E.coli-derived asparaginase |
| Crizotinib | Relapsed or refractory, systemic ALK-positive anaplastic large cell lymphoma |
| Ibrutinib | Waldenstrom’s Macroglobulinaemia |
| Ibrutinib | Mantle cell lymphoma; received at least one prior therapy |
| Idelalisib | Relapsed follicular lymphoma; received at least two prior systemic therapies |
| Nivolumab | Relapsed or refractory classical Hodgkin lymphoma after ASCT and treatment with brentuximab vedotin |
| Obinutuzumab | Follicular lymphoma that has not responded to or progressed within 6 months after treatment with rituximab or a rituximab-containing regimen |
| Obinutuzumab | Previously untreated stage II bulky, III or IV follicular lymphoma |
| Pembrolizumab | Treatment of patients with relapsed or refractory classical Hodgkin lymphoma, who have failed ASCT or following at least two prior therapies when ASCT is not a treatment option |
| Pembrolizumab | Refractory primary mediastinal B-cell lymphoma, or who have relapsed after 2 or more prior lines of therapy |
| Rituximab (subcutaneous) | Maintenance treatment of follicular lymphoma who have responded to induction therapy |
| Rituximab (subcutaneous) | CD20 + diffuse large B-cell non-Hodgkin lymphoma |
| Rituximab (subcutaneous) | Previously untreated stage III-IV follicular lymphoma |
| Romidepsin | Cutaneous T-cell lymphoma; received at least one prior systemic therapy |
ASCT autologous stem cell transplant